Analytical validation and implementation of a targeted long-read ONT sequencing assay for the identification of fungal pathogens from primary specimens
In brief
Targeted long-read sequencing matched Sanger results in 98.9% of fungal tests
In 89 clinical specimens, the targeted Oxford Nanopore assay agreed with Sanger sequencing in 88 (98.9%), including all 58 formalin-fixed samples; it identified 45 of 46 Sanger-positive specimens and correctly classified all 43 negatives. The results support comparable identification performance, but relative read abundance cannot be treated as a measure of fungal burden.
- Journal
- Diagnostic microbiology and infectious disease (Q2)
- Published
- 16 November 2026
- Study design
- Unclassified
- Evidence level
- Level 5, Expert Opinion (CEBM 5)
- Authors
- Manal Tadros, Farhad Gharabaghi, Lynette Lau, Christian Marshall, Aaron Campigotto
- PMID
- 43063767
- DOI
- 10.1016/j.diagmicrobio.2026.117754
Why clinicians should know about it
- Picked for Microbiology (medical) (top studies of the week, 22 November 2026): Clinical validation of targeted long-read fungal pathogen sequencing
Abstract
Invasive fungal infections (IFIs) are serious diseases with significant morbidity and mortality in immunocompromised patients. Conventional diagnostic methods such as culture and histopathology have low sensitivity and a prolonged turnaround time. Next-generation sequencing (NGS) technologies, including long-read sequencing, have provided novel modalities for detecting and identifying microorganisms. The clinical utility of newer sequencing technologies in detecting fungal pathogens has been limited. In this work, we summarize the analytical validation of a targeted Oxford Nanopore Technologies (ONT)-based sequencing assay, in comparison with targeted Sanger sequencing as a reference method, for the identification of fungal pathogens in clinical specimens. The diagnostic performance of the targeted ONT assay was assessed using extracted DNA from 89 specimens (46 positive and 43 negative), previously tested using Sanger sequencing. The overall agreement between our targeted ONT assay and Sanger sequencing was 98.9% (88/89; 95% CI, 93.9%-99.8%). Positive percentage agreement was 97.8% (45/46; 95% CI, 88.7%-99.6%), and negative percentage agreement was 100% (43/43; 95% CI, 91.8%-100%). For FFPE specimens (n = 58), there was 100% agreement between ONT and Sanger sequencing. For unfixed specimens (n = 31), agreement was 97%. This study showed that the targeted fungal ONT sequencing assay had performance comparable to Sanger sequencing. Potential advantages include detection of a clinically significant fungus in specimens containing environmental fungi, a parallel multiplexed workflow with reduced manual gel processing, and a relative read-abundance output. Because relative read abundance can be affected by PCR amplification bias, it should not be interpreted as a direct measure of tissue fungal burden.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.